C-reactive protein and end-stage renal disease.
The significance of CRP and inflammation has increased over time, especially in the end-stage renal disease (ESRD) population. From a simple marker it now appears that CRP is an active participant in pro-atherosclerotic phenomenon including local pro-inflammatory and thrombotic events. Studies in the general population indicate the usefulness of CRP in prognostication and in monitoring response to therapy. The clinical usefulness of CRP monitoring in chronic kidney disease (CKD) and especially in ESRD deserves closer study. In the meantime, the utility of CRP measurements for monitoring and treatment is on a case-by-case basis. Management of traditional cardiovascular risk factors should be considered. In the interest of optimizing therapy it is prudent to use biocompatible membranes and ultrapure water. A careful search for infectious processes in dialysis patients is recommended, with special attention to vascular access sites, periodontitis, gastritis, and other potentially chronic or covert infections. ACE-inhibitor use should be maximized in all eligible CKD patients. The data on the use of statins in ESRD have been generally positive but await further validation. Individualized use for selected patients is probably beneficial.
Lacson
Eduardo
E
Fresenius Medical Care-North America, 95 Hayden Avenue, Lexington, MA 02421, USA. elacsonj@fmc-na.com
Levin
Nathan W
NW
D000740:Anemia / Q000378:metabolism; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000187:drug effects / Q000378:metabolism*; D002318:Cardiovascular Diseases / Q000378:metabolism / Q000401:mortality; D004730:Endothelium, Vascular / Q000378:metabolism; D006801:Humans; D007239:Infections / Q000378:metabolism; D007249:Inflammation / Q000378:metabolism; D007676:Kidney Failure, Chronic / Q000378:metabolism* / Q000628:therapy; D009752:Nutritional Status; D006435:Renal Dialysis; D012307:Risk Factors
D015415:Biomarkers; D002097:C-Reactive Protein